For instance, RBM15 upregulation in acute myeloid leukemia, hepatocellular carcinoma, and breast cancer is associated with accelerated tumor progression and unfavorable outcomes, whereas its downregulation in certain solid tumors may reflect impaired tumor-suppressive pathways (Bhat et al., 2024). Here, RBM15 is linked to neoplasm.